Follow
Irmela Jeremias
Irmela Jeremias
Verified email at helmholtz-muenchen.de - Homepage
Title
Cited by
Cited by
Year
The target landscape of clinical kinase drugs
S Klaeger, S Heinzlmeir, M Wilhelm, H Polzer, B Vick, PA Koenig, ...
Science 358 (6367), eaan4368, 2017
7372017
CD95 ligand (Fas-L/APO-1L) and tumor necrosis factor-related apoptosis-inducing ligand mediate ischemia-induced apoptosis in neurons
A Martin-Villalba, I Herr, I Jeremias, M Hahne, R Brandt, J Vogel, ...
Journal of Neuroscience 19 (10), 3809-3817, 1999
6141999
Small-molecule inhibition of METTL3 as a strategy against myeloid leukaemia
E Yankova, W Blackaby, M Albertella, J Rak, E De Braekeleer, ...
Nature 593 (7860), 597-601, 2021
6092021
TRAIL/Apo‐2‐ligand‐induced apoptosis in human T cells
I Jeremias, I Herr, T Boehler, KM Debatin
European journal of immunology 28 (1), 143-152, 1998
4111998
TRAIL induced survival and proliferation in cancer cells resistant towards TRAIL-induced apoptosis mediated by NF-κB
H Ehrhardt, S Fulda, I Schmid, J Hiscott, KM Debatin, I Jeremias
Oncogene 22 (25), 3842-3852, 2003
3912003
Interleukin-1 receptor antagonist and interleukin-6 for early diagnosis of neonatal sepsis 2 days before clinical manifestation
H Küster, M Weiss, AE Willeitner, S Detlefsen, I Jeremias, J Zbojan, ...
The Lancet 352 (9136), 1271-1277, 1998
3571998
Involvement of CD95/Apo1/Fas in cell death after myocardial ischemia
I Jeremias, C Kupatt, A Martin-Villalba, H Habazettl, J Schenkel, ...
Circulation 102 (8), 915-920, 2000
3472000
The public repository of xenografts enables discovery and randomized phase II-like trials in mice
EC Townsend, MA Murakami, A Christodoulou, AL Christie, J Köster, ...
Cancer cell 29 (4), 574-586, 2016
3282016
Betulinic acid: a new cytotoxic agent against malignant brain‐tumor cells
S Fulda, I Jeremias, HH Steiner, T Pietsch, KM Debatin
International journal of cancer 82 (3), 435-441, 1999
3121999
Inhibition of nuclear factor κB activation attenuates apoptosis resistance in lymphoid cells
I Jeremias, C Kupatt, B Baumann, I Herr, T Wirth, KM Debatin
Blood, The Journal of the American Society of Hematology 91 (12), 4624-4631, 1998
3041998
Characterization of rare, dormant, and therapy-resistant cells in acute lymphoblastic leukemia
S Ebinger, EZ Özdemir, C Ziegenhain, S Tiedt, CC Alves, M Grunert, ...
Cancer cell 30 (6), 849-862, 2016
2692016
Blockade of the PD-1/PD-L1 axis augments lysis of AML cells by the CD33/CD3 BiTE antibody construct AMG 330: reversing a T-cell-induced immune escape mechanism
C Krupka, P Kufer, R Kischel, G Zugmaier, FS Lichtenegger, T Köhnke, ...
Leukemia 30 (2), 484-491, 2016
2602016
Loss of the histone methyltransferase EZH2 induces resistance to multiple drugs in acute myeloid leukemia
S Göllner, T Oellerich, S Agrawal-Singh, T Schenk, HU Klein, C Rohde, ...
Nature medicine 23 (1), 69-78, 2017
2252017
Somatic gene editing ameliorates skeletal and cardiac muscle failure in pig and human models of Duchenne muscular dystrophy
A Moretti, L Fonteyne, F Giesert, P Hoppmann, AB Meier, T Bozoglu, ...
Nature medicine 26 (2), 207-214, 2020
2012020
Small molecule XIAP inhibitors cooperate with TRAIL to induce apoptosis in childhood acute leukemia cells and overcome Bcl-2–mediated resistance
M Fakler, S Loeder, M Vogler, K Schneider, I Jeremias, KM Debatin, ...
Blood, The Journal of the American Society of Hematology 113 (8), 1710-1722, 2009
1742009
Betulinic acid-induced apoptosis in leukemia cells
H Ehrhardt, S Fulda, M Führer, KM Debatin, I Jeremias
Leukemia 18 (8), 1406-1412, 2004
1722004
Deep learning reveals cancer metastasis and therapeutic antibody targeting in the entire body
C Pan, O Schoppe, A Parra-Damas, R Cai, MI Todorov, G Gondi, ...
Cell 179 (7), 1661-1676. e19, 2019
1692019
MLL-rearranged acute lymphoblastic leukemias activate BCL-2 through H3K79 methylation and are sensitive to the BCL-2-specific antagonist ABT-199
JM Benito, L Godfrey, K Kojima, L Hogdal, M Wunderlich, H Geng, I Marzo, ...
Cell reports 13 (12), 2715-2727, 2015
1432015
MycN and IFNγ cooperate in apoptosis of human neuroblastoma cells
W Lutz, S Fulda, I Jeremias, KM Debatin, M Schwab
Oncogene 17 (3), 339-346, 1998
1301998
Smac mimetic bypasses apoptosis resistance in FADD-or caspase-8-deficient cells by priming for tumor necrosis factor α-induced necroptosis
B Laukens, C Jennewein, B Schenk, N Vanlangenakker, A Schier, ...
Neoplasia 13 (10), 971-IN29, 2011
1252011
The system can't perform the operation now. Try again later.
Articles 1–20